Skip to main content
Top
Published in: Current Obstetrics and Gynecology Reports 2/2017

01-06-2017 | Family Planning (A Burke, Section Editor)

Intrauterine Devices and Contraceptive Implants: Overview of Options and Updates on Method Use

Authors: M. K. Findley, E. E. Levi, M. V. Dragoman

Published in: Current Obstetrics and Gynecology Reports | Issue 2/2017

Login to get access

Abstract

Purpose of Review

Intrauterine devices (IUDs) and contraceptive implants offer safe and highly effective long-acting reversible contraception (LARC) without requiring routine effort from users. A majority of women who choose these methods report high satisfaction; 12-month continuation rates typically exceed 80%. We summarize some of the latest research and recommendations for use of currently available LARC methods to promote high-quality service delivery.

Recent Findings

New hormonal LARC methods are available, and research suggests that the duration of contraceptive protection for some existing methods extends beyond current manufacturer instructions. Updated evidence-based guidelines recommend that most women, including women with various medical conditions, can safely use IUDs and/or contraceptive implants. Initiation can be timed to whenever pregnancy is reasonably excluded, and few, if any, examinations or tests are required prior to insertion. We highlight some considerations for the use of these methods by adolescents and by women who are postpartum or breastfeeding and immediately following abortion.

Summary

LARC methods offer many attractive features to women seeking contraception, and there are a growing number of options available for women to consider. Evidence-based recommendations should guide determinations of medical eligibility. Implementing best practices for safe and effective provision of LARC and optimizing opportunities for contraceptive initiation enables providers to better respond to women’s needs. Access to contraception and family planning, including LARC, is critical to the health and well-being of women, families, and communities worldwide.
Literature
1.
go back to reference United Nations Department of Economic and Social Affairs—Population Division. Trends in Contraceptive Use Worldwide 2015. United Nations Department of Economic and Social Affairs—Population Division. Trends in Contraceptive Use Worldwide 2015.
2.
go back to reference • Kavanaugh ML, Jerman J, Finer LB. Changes in use of long-acting reversible contraceptive methods among U.S. women, 2009–2012. Obstet Gynecol. 2015;126(5):917–27. doi:10.1097/AOG.0000000000001094. This article used national U.S. data to compare rates of LARC use between 2008–2010 and 2011–2013. Important findings include an overal increase in use of LARC from 8.5 to 11.6%. Latina women, women with private insurance, women with less than two sexual partners in the last year, and nulliparous women saw the greatest increases in LARC uptake CrossRefPubMedPubMedCentral • Kavanaugh ML, Jerman J, Finer LB. Changes in use of long-acting reversible contraceptive methods among U.S. women, 2009–2012. Obstet Gynecol. 2015;126(5):917–27. doi:10.​1097/​AOG.​0000000000001094​. This article used national U.S. data to compare rates of LARC use between 2008–2010 and 2011–2013. Important findings include an overal increase in use of LARC from 8.5 to 11.6%. Latina women, women with private insurance, women with less than two sexual partners in the last year, and nulliparous women saw the greatest increases in LARC uptake CrossRefPubMedPubMedCentral
14.
go back to reference Bahamondes L, Brache V, Meirik O, Ali M, Habib N, Landoulsi S, et al. A 3-year multicentre randomized controlled trial of etonogestrel- and levonorgestrel-releasing contraceptive implants, with non-randomized matched copper-intrauterine device controls. Hum Reprod. 2015;30(11):2527–38. doi:10.1093/humrep/dev221.CrossRefPubMed Bahamondes L, Brache V, Meirik O, Ali M, Habib N, Landoulsi S, et al. A 3-year multicentre randomized controlled trial of etonogestrel- and levonorgestrel-releasing contraceptive implants, with non-randomized matched copper-intrauterine device controls. Hum Reprod. 2015;30(11):2527–38. doi:10.​1093/​humrep/​dev221.CrossRefPubMed
15.
go back to reference Kaneshiro B, Aeby T. Long-term safety, efficacy, and patient acceptability of the intrauterine copper T-380A contraceptive device. Int J Women’s Health. 2010;2:211–20. doi:10.2147/IJWH.S6914.CrossRef Kaneshiro B, Aeby T. Long-term safety, efficacy, and patient acceptability of the intrauterine copper T-380A contraceptive device. Int J Women’s Health. 2010;2:211–20. doi:10.​2147/​IJWH.​S6914.CrossRef
16.
go back to reference • Creinin MD, Jansen R, Starr RM, Gobburu J, Gopalakrishnan M, Olariu A. Levonorgestrel release rates over 5 years with the Liletta (R) 52-mg intrauterine system. Contraception. 2016;94(4):353–6. doi:10.1016/j.contraception.2016.04.010. This analysis of LNG release rates of the Liletta® 52-mg LNG IUD shows that serum levels of LNG continue to be within the therapeutic range at 5 years’ duration, suggesting that the device will continue to be effective through 5 years. This study formed the basis of an ongoing FDA application to extend the approved duration of the Liletta® from 3 to 5 years CrossRefPubMed • Creinin MD, Jansen R, Starr RM, Gobburu J, Gopalakrishnan M, Olariu A. Levonorgestrel release rates over 5 years with the Liletta (R) 52-mg intrauterine system. Contraception. 2016;94(4):353–6. doi:10.​1016/​j.​contraception.​2016.​04.​010. This analysis of LNG release rates of the Liletta® 52-mg LNG IUD shows that serum levels of LNG continue to be within the therapeutic range at 5 years’ duration, suggesting that the device will continue to be effective through 5 years. This study formed the basis of an ongoing FDA application to extend the approved duration of the Liletta® from 3 to 5 years CrossRefPubMed
18.
go back to reference Liletta (R) prescribing information. Medicines360, San Francisco, CA. 2016. Accessed 15 Feb 2017. Liletta (R) prescribing information. Medicines360, San Francisco, CA. 2016. Accessed 15 Feb 2017.
27.
go back to reference Hidalgo M, Bahamondes L, Perrotti M, Diaz J, Dantas-Monteiro C, Petta C. Bleeding patterns and clinical performance of the levonorgestrel-releasing intrauterine system (Mirena) up to two years. Contraception. 2002;65(2):129–32. doi:10.1016/s0010-7824(01)00302-x.CrossRefPubMed Hidalgo M, Bahamondes L, Perrotti M, Diaz J, Dantas-Monteiro C, Petta C. Bleeding patterns and clinical performance of the levonorgestrel-releasing intrauterine system (Mirena) up to two years. Contraception. 2002;65(2):129–32. doi:10.​1016/​s0010-7824(01)00302-x.CrossRefPubMed
31.
go back to reference Zheng SR, Zheng HM, Qian SZ, Sang GW, Kaper RF. A randomized multicenter study comparing the efficacy and bleeding pattern of a single-rod (Implanon) and a six-capsule (Norplant) hormonal contraceptive implant. Contraception. 1999;60(1):1–8. doi:10.1016/S0010-7824(99)00053-0.CrossRefPubMed Zheng SR, Zheng HM, Qian SZ, Sang GW, Kaper RF. A randomized multicenter study comparing the efficacy and bleeding pattern of a single-rod (Implanon) and a six-capsule (Norplant) hormonal contraceptive implant. Contraception. 1999;60(1):1–8. doi:10.​1016/​S0010-7824(99)00053-0.CrossRefPubMed
33.
go back to reference Mansour D, Korver T, Marintcheva-Petrova M, Fraser IS. The effects of Implanon on menstrual bleeding patterns. Eur J Contracep Reprod Health Care: Off J Eur Soc Contracep. 2008;13(Suppl 1):13–28. doi:10.1080/13625180801959931.CrossRef Mansour D, Korver T, Marintcheva-Petrova M, Fraser IS. The effects of Implanon on menstrual bleeding patterns. Eur J Contracep Reprod Health Care: Off J Eur Soc Contracep. 2008;13(Suppl 1):13–28. doi:10.​1080/​1362518080195993​1.CrossRef
34.
go back to reference Hou MY, McNicholas C, Creinin MD. Combined oral contraceptive treatment for bleeding complaints with the etonogestrel contraceptive implant: a randomised controlled trial. Eur J Contracep Reprod Health Care: Off J Eur Soc Contracep. 2016;21(5):361–6. doi:10.1080/13625187.2016.1210122.CrossRef Hou MY, McNicholas C, Creinin MD. Combined oral contraceptive treatment for bleeding complaints with the etonogestrel contraceptive implant: a randomised controlled trial. Eur J Contracep Reprod Health Care: Off J Eur Soc Contracep. 2016;21(5):361–6. doi:10.​1080/​13625187.​2016.​1210122.CrossRef
35.
go back to reference Guiahi M, McBride M, Sheeder J, Teal S. Short-term treatment of bothersome bleeding for etonogestrel implant users using a 14-day oral contraceptive pill regimen: a randomized controlled trial. Obstet Gynecol. 2015;126(3):508–13. doi:10.1097/AOG.0000000000000974.CrossRefPubMed Guiahi M, McBride M, Sheeder J, Teal S. Short-term treatment of bothersome bleeding for etonogestrel implant users using a 14-day oral contraceptive pill regimen: a randomized controlled trial. Obstet Gynecol. 2015;126(3):508–13. doi:10.​1097/​AOG.​0000000000000974​.CrossRefPubMed
36.
go back to reference Kulier R, Helmerhorst FM, O’Brien P, Usher-Patel M, d’Arcangues C. Copper containing, framed intra-uterine devices for contraception. Cochrane Database Syst Rev. 2006;3:CD005347. doi:10.1002/14651858.CD005347.pub2. Kulier R, Helmerhorst FM, O’Brien P, Usher-Patel M, d’Arcangues C. Copper containing, framed intra-uterine devices for contraception. Cochrane Database Syst Rev. 2006;3:CD005347. doi:10.​1002/​14651858.​CD005347.​pub2.
38.
go back to reference Curtis KM, Jatlaoui TC, Tepper NK, Zapata LB, Horton LG, Jamieson DJ, et al. U.S. selected practice recommendations for contraceptive use, 2016. MMWR Recomm Rep. 2016;65(4):1–66. doi:10.15585/mmwr.rr6504a1.CrossRef Curtis KM, Jatlaoui TC, Tepper NK, Zapata LB, Horton LG, Jamieson DJ, et al. U.S. selected practice recommendations for contraceptive use, 2016. MMWR Recomm Rep. 2016;65(4):1–66. doi:10.​15585/​mmwr.​rr6504a1.CrossRef
39.
go back to reference World Health Organization. Selected practice recommendations for contraceptive use. Third edition 20162016. World Health Organization. Selected practice recommendations for contraceptive use. Third edition 20162016.
40.
go back to reference World Health Organization. Selected practice recommendations for contraceptive use, 2008 update. 2008. World Health Organization. Selected practice recommendations for contraceptive use, 2008 update. 2008.
42.
43.
go back to reference Turok DK, Godfrey EM, Wojdyla D, Dermish A, Torres L, Wu SC. Copper T380 intrauterine device for emergency contraception: highly effective at any time in the menstrual cycle. Hum Reprod. 2013;28(10):2672–6. doi:10.1093/humrep/det330.CrossRefPubMed Turok DK, Godfrey EM, Wojdyla D, Dermish A, Torres L, Wu SC. Copper T380 intrauterine device for emergency contraception: highly effective at any time in the menstrual cycle. Hum Reprod. 2013;28(10):2672–6. doi:10.​1093/​humrep/​det330.CrossRefPubMed
44.
48.
go back to reference World Health Organization. Adolescent Pregnancy. Geneva, Switzerland 2014 September. World Health Organization. Adolescent Pregnancy. Geneva, Switzerland 2014 September.
49.
50.
go back to reference American College of Obstetricians and Gynecologists. Adolescents and long-acting reversible contraception: implants and intrauterine devices. Obstet Gynecol. 2012;120:983–8.CrossRef American College of Obstetricians and Gynecologists. Adolescents and long-acting reversible contraception: implants and intrauterine devices. Obstet Gynecol. 2012;120:983–8.CrossRef
51.
go back to reference Family Planning 2020. Global Consensus Statement: Expanding Contraceptive Choice for Adolescents and Youth to Include Long-Acting Reversible Contraception 2015 October 20. Family Planning 2020. Global Consensus Statement: Expanding Contraceptive Choice for Adolescents and Youth to Include Long-Acting Reversible Contraception 2015 October 20.
56.
go back to reference Hubacher D, Lara-Ricalde R, Taylor DJ, Guerra-Infante F, Guzman-Rodriguez R. Use of copper intrauterine devices and the risk of tubal infertility among nulligravid women. N Engl J Med. 2001;345(8):561–7. doi:10.1056/NEJMoa010438.CrossRefPubMed Hubacher D, Lara-Ricalde R, Taylor DJ, Guerra-Infante F, Guzman-Rodriguez R. Use of copper intrauterine devices and the risk of tubal infertility among nulligravid women. N Engl J Med. 2001;345(8):561–7. doi:10.​1056/​NEJMoa010438.CrossRefPubMed
58.
go back to reference World Health Organization. Programming strategies for postpartum family planning. Geneva, Switzerland 2013. World Health Organization. Programming strategies for postpartum family planning. Geneva, Switzerland 2013.
60.
70.
go back to reference WHO Guidelines Approved by the Guidelines Review Committee. Medical Eligibility Criteria for Contraceptive Use. Geneva: World Health Organization Copyright (c) World Health Organization 2015.; 2015. WHO Guidelines Approved by the Guidelines Review Committee. Medical Eligibility Criteria for Contraceptive Use. Geneva: World Health Organization Copyright (c) World Health Organization 2015.; 2015.
71.
go back to reference Horton LG, Folger SG, Berry-Bibee E, Jatlaoui TC, Tepper NK, Curtis KM. Research gaps from evidence-based contraception guidance: the US medical eligibility criteria for contraceptive use, 2016, and the US selected practice recommendations for contraceptive use, 2016. Contraception. 2016;94(6):582–9. doi:10.1016/j.contraception.2016.07.017.CrossRefPubMed Horton LG, Folger SG, Berry-Bibee E, Jatlaoui TC, Tepper NK, Curtis KM. Research gaps from evidence-based contraception guidance: the US medical eligibility criteria for contraceptive use, 2016, and the US selected practice recommendations for contraceptive use, 2016. Contraception. 2016;94(6):582–9. doi:10.​1016/​j.​contraception.​2016.​07.​017.CrossRefPubMed
72.
73.
go back to reference World Health Organization. Clinical practice handbook for safe abortion. Geneva, Switzerland 2014. World Health Organization. Clinical practice handbook for safe abortion. Geneva, Switzerland 2014.
74.
go back to reference • Raymond EG, Weaver MA, Tan YL, Louie KS, Bousieguez M, Lugo-Hernandez EM, et al. Effect of immediate compared with delayed insertion of etonogestrel implants on medical abortion efficacy and repeat pregnancy: a randomized controlled trial. Obstet Gynecol. 2016;127(2):306–12. doi:10.1097/AOG.0000000000001274. This randomized trial randomized women who desired an ETG contraceptive implant at the time of medical abortion to placement at the time of mifepristone administration or after confirmation that the abortion was complete. They found that insertion of the ETG implant at the time of mifepristone administration did not increase failure rate and did increase patient satisfaction CrossRefPubMed • Raymond EG, Weaver MA, Tan YL, Louie KS, Bousieguez M, Lugo-Hernandez EM, et al. Effect of immediate compared with delayed insertion of etonogestrel implants on medical abortion efficacy and repeat pregnancy: a randomized controlled trial. Obstet Gynecol. 2016;127(2):306–12. doi:10.​1097/​AOG.​0000000000001274​. This randomized trial randomized women who desired an ETG contraceptive implant at the time of medical abortion to placement at the time of mifepristone administration or after confirmation that the abortion was complete. They found that insertion of the ETG implant at the time of mifepristone administration did not increase failure rate and did increase patient satisfaction CrossRefPubMed
75.
go back to reference Hognert H, Kopp Kallner H, Cameron S, Nyrelli C, Jawad I, Heller R, et al. Immediate versus delayed insertion of an etonogestrel releasing implant at medical abortion—a randomized controlled equivalence trial. Hum Reprod. 2016;31(11):2484–90. doi:10.1093/humrep/dew238.CrossRefPubMed Hognert H, Kopp Kallner H, Cameron S, Nyrelli C, Jawad I, Heller R, et al. Immediate versus delayed insertion of an etonogestrel releasing implant at medical abortion—a randomized controlled equivalence trial. Hum Reprod. 2016;31(11):2484–90. doi:10.​1093/​humrep/​dew238.CrossRefPubMed
77.
go back to reference Rowe PJ, Boccard S, Farley TMM, Peregoudov S, Reinprayoon D, Koetsawang S, et al. Long-term reversible contraception—twelve years of experience with the TCu380A and TCu220C. Contraception. 1997;56(6):341–52. Rowe PJ, Boccard S, Farley TMM, Peregoudov S, Reinprayoon D, Koetsawang S, et al. Long-term reversible contraception—twelve years of experience with the TCu380A and TCu220C. Contraception. 1997;56(6):341–52.
80.
go back to reference • McNicholas C, Maddipati R, Zhao QH, Swor E, Peipert JF. Use of the etonogestrel implant and levonorgestrel intrauterine device beyond the US Food and Drug Administration-approved duration. Obstet Gynecol. 2015;125(3):599–604. doi:10.1097/aog.0000000000000690. This analysis of the observational Contraceptive CHOICE Project prospectively followed 237 women using the ETG contraceptive implant and 263 LNG-20 IUD users. Of 123 women who continued use of the implant at 4 years and 34 women who continued use at 5 years, zero pregnancies were detected. Of the 108 women who continued to use the LNG-20 IUD at 6 years, one pregnancy was detected CrossRefPubMedPubMedCentral • McNicholas C, Maddipati R, Zhao QH, Swor E, Peipert JF. Use of the etonogestrel implant and levonorgestrel intrauterine device beyond the US Food and Drug Administration-approved duration. Obstet Gynecol. 2015;125(3):599–604. doi:10.​1097/​aog.​0000000000000690​. This analysis of the observational Contraceptive CHOICE Project prospectively followed 237 women using the ETG contraceptive implant and 263 LNG-20 IUD users. Of 123 women who continued use of the implant at 4 years and 34 women who continued use at 5 years, zero pregnancies were detected. Of the 108 women who continued to use the LNG-20 IUD at 6 years, one pregnancy was detected CrossRefPubMedPubMedCentral
82.
go back to reference Ali M, Akin A, Bahamondes L, Brache V, Habib N, Landoulsi S, et al. Extended use up to 5 years of the etonogestrel-releasing subdermal contraceptive implant: comparison to levonorgestrel-releasing subdermal implant. Hum Reprod. 2016;31(11):2491–8. doi:10.1093/humrep/dew222.CrossRefPubMedPubMedCentral Ali M, Akin A, Bahamondes L, Brache V, Habib N, Landoulsi S, et al. Extended use up to 5 years of the etonogestrel-releasing subdermal contraceptive implant: comparison to levonorgestrel-releasing subdermal implant. Hum Reprod. 2016;31(11):2491–8. doi:10.​1093/​humrep/​dew222.CrossRefPubMedPubMedCentral
83.
go back to reference Kiriwat O, Patanayindee A, Koetsawang S, Korver T, Bennink HJ. A 4-year pilot study on the efficacy and safety of Implanon, a single-rod hormonal contraceptive implant, in healthy women in Thailand. Eur J Contracep Reprod Health Care: Off J Eur Soc Contracep. 1998;3(2):85–91. doi:10.3109/13625189809051409.CrossRef Kiriwat O, Patanayindee A, Koetsawang S, Korver T, Bennink HJ. A 4-year pilot study on the efficacy and safety of Implanon, a single-rod hormonal contraceptive implant, in healthy women in Thailand. Eur J Contracep Reprod Health Care: Off J Eur Soc Contracep. 1998;3(2):85–91. doi:10.​3109/​1362518980905140​9.CrossRef
84.
go back to reference Zheng SR, Zheng HM, Qian SZ, Sang GW, Kaper RF. A long-term study of the efficacy and acceptability of a single-rod hormonal contraceptive implant (Implanon) in healthy women in China. Eur J Contracep Reprod Health Care: Off J Eur Soc Contracep. 1999;4(2):85–93. doi:10.3109/13625189909064009.CrossRef Zheng SR, Zheng HM, Qian SZ, Sang GW, Kaper RF. A long-term study of the efficacy and acceptability of a single-rod hormonal contraceptive implant (Implanon) in healthy women in China. Eur J Contracep Reprod Health Care: Off J Eur Soc Contracep. 1999;4(2):85–93. doi:10.​3109/​1362518990906400​9.CrossRef
Metadata
Title
Intrauterine Devices and Contraceptive Implants: Overview of Options and Updates on Method Use
Authors
M. K. Findley
E. E. Levi
M. V. Dragoman
Publication date
01-06-2017
Publisher
Springer US
Published in
Current Obstetrics and Gynecology Reports / Issue 2/2017
Electronic ISSN: 2161-3303
DOI
https://doi.org/10.1007/s13669-017-0200-8

Other articles of this Issue 2/2017

Current Obstetrics and Gynecology Reports 2/2017 Go to the issue

Care for the Transgender Patient (C Unger, Section Editor)

Reproductive and Obstetrical Care for Transgender Patients

Reproductive Endocrinology and Infertility (REI) (R Anchan, Section Editor)

Genetic Screening and Early Recurrent Pregnancy Loss

Care for the Transgender Patient (C Unger, Section Editor)

Vaginoplasty for the Transgender Woman

Family Planning (A Burke, Section Editor)

Misoprostol in Abortion Care: Review and Update